SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Short Candidates
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: gotmojo who wrote (610)11/30/2003 9:02:56 AM
From: GREENLAW4-7  Read Replies (3) of 897
 
Gomo, ONXX showed up on my alert list last week. I wrote a piece about the lack of any fundamentals, as well as lack of potential market for drug over on Auric's short site.

I am amazed this stock did not tank on the Phase 2 results were incidently failed every single end point but one. Even those results look very suspect if you look closer at the actual study and number of participants.

The most questionable aspect of this stock and its current 800 mil market cap is the fact the Kidney Cancer market is not even close to 800 mil a year. So even if it had a drug that was approved, I doubt sincerely this stock would have even 1/2 its current market cap.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News